Literature DB >> 33370345

Prediction of radiation pneumonitis using dose-volume histogram parameters with high attenuation in two types of cancer: A retrospective study.

Yasuki Uchida1, Takuya Tsugawa2, Sachiko Tanaka-Mizuno3,4, Kazuo Noma5, Ken Aoki2, Kentaro Fukunaga1, Hiroaki Nakagawa1, Daisuke Kinose1, Masafumi Yamaguchi1, Makoto Osawa1,6, Taishi Nagao1, Emiko Ogawa1,7, Yasutaka Nakano1.   

Abstract

The constraint values of dose-volume histogram (DVH) parameters for radiation pneumonitis (RP) prediction have not been uniform in previous studies. We compared the differences between conventional DVH parameters and DVH parameters with high attenuation volume (HAV) in CT imaging in both esophageal cancer and lung cancer patients to determine the most suitable DVH parameters in predicting RP onset. Seventy-seven and 72 patients who underwent radiation therapy for lung cancer and esophageal cancer, respectively, were retrospectively assessed. RP was valued according to the Common Terminology Criteria for Adverse Events. We quantified HAV with quantitative computed tomography analysis. We compared conventional DVH parameters and DVH parameters with HAV in both groups of patients. Then, the thresholds of DVH parameters that predicted symptomatic RP and the differences in threshold of DVH parameters between lung cancer and esophageal cancer patient groups were compared. The predictive performance of DVH parameters for symptomatic RP was compared using the area under the receiver operating characteristic curve. Mean lung dose, HAV30% (the proportion of the lung with HAV receiving ≥30 Gy), and HAV20% were the top three parameters in lung cancer, while HAV10%, HAV5%, and V10 (the percentage of lung volume receiving 10 Gy or more) were the top three in esophageal cancer. By comparing the differences in the threshold for parameters predicting RP between the two cancers, we saw that HAV30% retained the same value in both cancers. DVH parameters with HAV showed narrow differences in the threshold between the two cancer patient groups compared to conventional DVH parameters. DVH parameters with HAV may have higher commonality than conventional DVH parameters in both patient groups tested.

Entities:  

Mesh:

Year:  2020        PMID: 33370345      PMCID: PMC7769248          DOI: 10.1371/journal.pone.0244143

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  24 in total

1.  Association of computed tomography-detected pulmonary interstitial changes with severe radiation pneumonitis for patients treated with thoracic radiotherapy.

Authors:  Naoko Sanuki; Asami Ono; Eiji Komatsu; Noritaka Kamei; Shinji Akamine; Tohru Yamazaki; Syunji Mizunoe; Toru Maeda
Journal:  J Radiat Res       Date:  2012       Impact factor: 2.724

2.  Adding ipsilateral V20 and V30 to conventional dosimetric constraints predicts radiation pneumonitis in stage IIIA-B NSCLC treated with combined-modality therapy.

Authors:  Sara Ramella; Lucio Trodella; Tommaso Claudio Mineo; Eugenio Pompeo; Gerardina Stimato; Diego Gaudino; Vincenzo Valentini; Francesco Cellini; Marzia Ciresa; Michele Fiore; Angelo Piermattei; Patrizia Russo; Alfredo Cesario; Rolando M D'Angelillo
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-01-01       Impact factor: 7.038

3.  Severe COPD is correlated with mild radiation pneumonitis following stereotactic body radiotherapy.

Authors:  Atsuya Takeda; Etsuo Kunieda; Toshio Ohashi; Yousuke Aoki; Yohei Oku; Tatsuji Enomoto; Koichiro Nomura; Madoka Sugiura
Journal:  Chest       Date:  2011-09-01       Impact factor: 9.410

4.  Normal range of emphysema and air trapping on CT in young men.

Authors:  Onno M Mets; Robert A van Hulst; Colin Jacobs; Bram van Ginneken; Pim A de Jong
Journal:  AJR Am J Roentgenol       Date:  2012-08       Impact factor: 3.959

5.  Genetic epidemiology of COPD (COPDGene) study design.

Authors:  Elizabeth A Regan; John E Hokanson; James R Murphy; Barry Make; David A Lynch; Terri H Beaty; Douglas Curran-Everett; Edwin K Silverman; James D Crapo
Journal:  COPD       Date:  2010-02       Impact factor: 2.409

6.  Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline Summary.

Authors:  Bryan J Schneider; Megan E Daly; Erin B Kennedy; Brendon M Stiles
Journal:  J Oncol Pract       Date:  2017-12-19       Impact factor: 3.840

7.  Quantitative computed tomography detects air trapping due to asthma.

Authors:  K B Newman; D A Lynch; L S Newman; D Ellegood; J D Newell
Journal:  Chest       Date:  1994-07       Impact factor: 9.410

8.  Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer.

Authors:  J-M Sun; Y C Ahn; E K Choi; M-J Ahn; J S Ahn; S-H Lee; D H Lee; H Pyo; S Y Song; S-H Jung; J S Jo; J Jo; H J Sohn; C Suh; J S Lee; S-W Kim; K Park
Journal:  Ann Oncol       Date:  2013-04-16       Impact factor: 32.976

9.  Epidemiology, radiology, and genetics of nicotine dependence in COPD.

Authors:  Deog Kyeom Kim; Craig P Hersh; George R Washko; John E Hokanson; David A Lynch; John D Newell; James R Murphy; James D Crapo; Edwin K Silverman
Journal:  Respir Res       Date:  2011-01-13

10.  Stereotactic body radiotherapy for Stage I lung cancer with chronic obstructive pulmonary disease: special reference to survival and radiation-induced pneumonitis.

Authors:  Toshihiko Inoue; Hiroya Shiomi; Ryoong-Jin Oh
Journal:  J Radiat Res       Date:  2015-04-16       Impact factor: 2.724

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.